QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Aldoxorubicin HCl
BIOLOGICAL: N-803
BIOLOGICAL: ETBX-011
BIOLOGICAL: ETBX-051
BIOLOGICAL: ETBX-061
BIOLOGICAL: GI-4000
BIOLOGICAL: GI-6207
BIOLOGICAL: GI-6301
BIOLOGICAL: haNK for Infusion
BIOLOGICAL: avelumab
BIOLOGICAL: bevacizumab
DRUG: Capecitabine
DRUG: Cisplatin
DRUG: Cyclophosphamide
DRUG: 5-Fluorouracil
DRUG: Leucovorin
DRUG: nab-Paclitaxel
PROCEDURE: SBRT

Sponsor

ImmunityBio, Inc.